- Home
- TLX vs AES Comparison
TLX vs AES Comparison
Compare TLX & AES Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLX
- AES
- Stock Information
- Founded
- TLX 2015
- AES 1981
- Country
- TLX Australia
- AES United States
- Employees
- TLX N/A
- AES N/A
- Industry
- TLX Biotechnology: Pharmaceutical Preparations
- AES Electric Utilities: Central
- Sector
- TLX Health Care
- AES Utilities
- Exchange
- TLX Nasdaq
- AES Nasdaq
- Market Cap
- TLX 6.0B
- AES 7.1B
- IPO Year
- TLX N/A
- AES 1991
- Fundamental
- Price
- TLX $16.71
- AES $10.18
- Analyst Decision
- TLX Strong Buy
- AES Buy
- Analyst Count
- TLX 1
- AES 7
- Target Price
- TLX $22.00
- AES $14.71
- AVG Volume (30 Days)
- TLX 28.3K
- AES 13.8M
- Earning Date
- TLX 01-01-0001
- AES 05-02-2025
- Dividend Yield
- TLX N/A
- AES 6.91%
- EPS Growth
- TLX 798.14
- AES 572.18
- EPS
- TLX 0.09
- AES 2.36
- Revenue
- TLX $484,687,790.00
- AES $12,278,000,000.00
- Revenue This Year
- TLX N/A
- AES $4.88
- Revenue Next Year
- TLX N/A
- AES $1.33
- P/E Ratio
- TLX $179.17
- AES $4.30
- Revenue Growth
- TLX 55.85
- AES N/A
- 52 Week Low
- TLX $13.61
- AES $9.86
- 52 Week High
- TLX $30.36
- AES $22.21
- Technical
- Relative Strength Index (RSI)
- TLX N/A
- AES 37.14
- Support Level
- TLX N/A
- AES $9.86
- Resistance Level
- TLX N/A
- AES $10.67
- Average True Range (ATR)
- TLX 0.00
- AES 0.58
- MACD
- TLX 0.00
- AES -0.19
- Stochastic Oscillator
- TLX 0.00
- AES 11.81
About TLX Telix Pharmaceuticals Limited American Depositary Shares
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.
About AES The AES Corporation
AES is a global power company that operates in 15 countries. Its generation portfolio as of year-end 2023 totals over 35 gigawatts, including renewable energy (53%), gas (27%), coal (18%), and oil (2%). AES has majority ownership and operates six electric utilities distributing power to more than 2.5 million customers.